PL2739293T3 - Sposoby i kompozycje wytwarzania wirusa krowianki - Google Patents
Sposoby i kompozycje wytwarzania wirusa krowiankiInfo
- Publication number
- PL2739293T3 PL2739293T3 PL12746243T PL12746243T PL2739293T3 PL 2739293 T3 PL2739293 T3 PL 2739293T3 PL 12746243 T PL12746243 T PL 12746243T PL 12746243 T PL12746243 T PL 12746243T PL 2739293 T3 PL2739293 T3 PL 2739293T3
- Authority
- PL
- Poland
- Prior art keywords
- compositions
- production
- methods
- vaccina virus
- vaccina
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24151—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161515724P | 2011-08-05 | 2011-08-05 | |
| PCT/US2012/049550 WO2013022764A1 (en) | 2011-08-05 | 2012-08-03 | Methods and compositions for production of vaccina virus |
| EP12746243.0A EP2739293B1 (en) | 2011-08-05 | 2012-08-03 | Methods and compositions for production of vaccina virus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2739293T3 true PL2739293T3 (pl) | 2020-11-16 |
Family
ID=46650950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL12746243T PL2739293T3 (pl) | 2011-08-05 | 2012-08-03 | Sposoby i kompozycje wytwarzania wirusa krowianki |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US9719105B2 (pl) |
| EP (1) | EP2739293B1 (pl) |
| JP (1) | JP6243333B2 (pl) |
| KR (1) | KR102022952B1 (pl) |
| CN (1) | CN103732236B (pl) |
| AU (1) | AU2012294606B2 (pl) |
| BR (1) | BR112014000787B1 (pl) |
| CA (1) | CA2841831C (pl) |
| DK (1) | DK2739293T3 (pl) |
| ES (1) | ES2813413T3 (pl) |
| PL (1) | PL2739293T3 (pl) |
| WO (1) | WO2013022764A1 (pl) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3169341T3 (pl) | 2014-07-16 | 2019-12-31 | Transgene Sa | Wirus onkolityczny do ekspresji modulatorów punktu kontroli immunologicznej |
| CA2975432A1 (en) | 2015-02-13 | 2016-08-18 | Transgene Sa | Immunotherapeutic vaccine and antibody combination therapy |
| WO2016131945A1 (en) | 2015-02-20 | 2016-08-25 | Transgene Sa | Combination product with autophagy modulator |
| ES2795010T3 (es) | 2015-06-19 | 2020-11-20 | Sillajen Inc | Composiciones y métodos para la embolización viral |
| CN106676071B (zh) * | 2015-11-06 | 2019-07-19 | 天士力创世杰（天津）生物制药有限公司 | HeLa-F细胞及其用途 |
| US20190134190A1 (en) | 2016-05-04 | 2019-05-09 | Transgene Sa | Combination therapy with cpg tlr9 ligand |
| EP3522920A2 (en) | 2016-10-10 | 2019-08-14 | Transgene SA | Immunotherapeutic product and mdsc modulator combination therapy |
| WO2018091680A1 (en) | 2016-11-18 | 2018-05-24 | Transgene Sa | Cowpox-based oncolytic vectors |
| CA3045228C (en) | 2016-12-28 | 2024-01-02 | Transgene Sa | Oncolytic viruses and therapeutic molecules |
| AU2018254626B2 (en) | 2017-04-21 | 2023-12-21 | Sillajen, Inc. | Oncolytic vaccinia virus and checkpoint inhibitor combination therapy |
| JP7334124B2 (ja) | 2017-06-21 | 2023-08-28 | トランジェーヌ | 個別化ワクチン |
| WO2019020543A1 (en) | 2017-07-28 | 2019-01-31 | Transgene Sa | ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS |
| EP3703723A4 (en) | 2017-10-31 | 2021-12-15 | KaliVir Immunotherapeutics, Inc. | ONCOLYTIC PLATFORM VECTOR FOR SYSTEMS ADMINISTRATION |
| WO2020011754A1 (en) | 2018-07-09 | 2020-01-16 | Transgene | Chimeric vaccinia viruses |
| EP3617230A1 (en) | 2018-09-03 | 2020-03-04 | BioInvent International AB | Novel antibodies and nucleotide sequences, and uses thereof |
| JP7625519B2 (ja) * | 2018-11-21 | 2025-02-03 | カリヴィル イムノセラピューティクス， インコーポレイテッド | ウイルスの製造 |
| BR112021012630A2 (pt) | 2018-12-28 | 2022-12-13 | Transgene Sa | Poxvírus modificado, método para produzir o poxvírus modificado e composição |
| KR102228267B1 (ko) | 2019-01-25 | 2021-03-17 | 바이로큐어 주식회사 | Bhk-21 세포를 이용한 바이러스 생산방법 |
| CN112143693B (zh) * | 2019-06-28 | 2024-12-27 | 杭州康万达医药科技有限公司 | 一种生产病毒的方法及收获液组合物 |
| EP3842065A1 (en) | 2019-12-23 | 2021-06-30 | Transgene | Process for designing a recombinant poxvirus for a therapeutic vaccine |
| JP7799323B2 (ja) * | 2020-06-22 | 2026-01-15 | コーロン ライフ サイエンス インコーポレイテッド | 浮遊細胞を用いたワクシニアウイルスの大量生産方法 |
| TW202217002A (zh) | 2020-07-13 | 2022-05-01 | 法商傳斯堅公司 | 免疫抑制之治療 |
| TW202227621A (zh) | 2020-11-19 | 2022-07-16 | 美商凱立凡爾免疫治療股份有限公司 | 重塑腫瘤微環境的溶瘤免疫療法 |
| WO2022148736A1 (en) | 2021-01-05 | 2022-07-14 | Transgene | Vectorization of muc1 t cell engager |
| JP2024516400A (ja) | 2021-04-30 | 2024-04-15 | カリヴィル イムノセラピューティクス， インコーポレイテッド | 修飾されたｍｈｃ発現のための腫瘍溶解性ウイルス |
| WO2023025899A2 (en) | 2021-08-26 | 2023-03-02 | Transgene | Delivery system for targeting genes of the interferon pathway |
| TW202321458A (zh) | 2021-09-22 | 2023-06-01 | 瑞典商生物創新國際公司 | 新穎抗體組合及其用途 |
| GB2614309A (en) | 2021-12-24 | 2023-07-05 | Stratosvir Ltd | Improved vaccinia virus vectors |
| CN114395538A (zh) * | 2022-01-19 | 2022-04-26 | 和元生物技术（上海）股份有限公司 | 一种促进重组病毒载体向细胞外分泌的方法 |
| WO2023213764A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf |
| WO2023213763A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab |
| JP2025523573A (ja) | 2022-07-01 | 2025-07-23 | トランジェーヌ | サーファクタントタンパク質－ｄとｔｎｆｓｆのメンバーを含んでなる融合タンパク質 |
| US20260049291A1 (en) | 2022-08-18 | 2026-02-19 | Transgene | Chimeric poxviruses |
| EP4677076A1 (en) * | 2023-03-10 | 2026-01-14 | Bavarian Nordic A/S | Methods of isolating poxviruses from avian cell cultures |
| WO2026041811A1 (en) | 2024-08-23 | 2026-02-26 | Transgene | Recombinant poxvirus and method for regulating the expression of toxic conditional gene products of said recombinant poxvirus in a producing cell |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6267965B1 (en) | 1981-12-24 | 2001-07-31 | Virogenetics Corporation | Recombinant poxvirus—cytomegalovirus compositions and uses |
| UA68327C2 (en) * | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
| WO2002042480A2 (en) * | 2000-11-23 | 2002-05-30 | Bavarian Nordic A/S | Modified vaccinia ankara virus variant |
| US7445924B2 (en) * | 2000-11-23 | 2008-11-04 | Bavarian Nordic A/S | Modified Vaccinia Ankara virus variant and cultivation method |
| KR101170653B1 (ko) | 2002-08-12 | 2012-08-03 | 제네렉스, 인코포레이티드 | 폭스바이러스 및 암과 관련된 방법 및 조성물 |
| US8574595B2 (en) * | 2005-04-11 | 2013-11-05 | Crucell Holland B.V. | Virus purification using ultrafiltration |
| US9180149B2 (en) * | 2005-09-07 | 2015-11-10 | Sillajen Biotherapeutics, Inc. | Systemic treatment of metastatic and/or systemically-disseminated cancers using GM-CSF-expressing poxviruses |
| CN101557824B (zh) * | 2006-08-07 | 2012-01-25 | 财团法人化学及血清疗法研究所 | 活牛痘疫苗的制备方法 |
| KR20080084528A (ko) * | 2007-03-15 | 2008-09-19 | 제네렉스 바이오테라퓨틱스 인크. | 종양살상형 백시니아 바이러스 암 치료 |
| US8003364B2 (en) * | 2007-05-14 | 2011-08-23 | Bavarian Nordic A/S | Purification of vaccinia viruses using hydrophobic interaction chromatography |
| WO2009048769A2 (en) * | 2007-10-10 | 2009-04-16 | Kirin Pharma Kabushiki Kaisha | Vaccinia virus h3l and b5r specific monoclonal antibodies and methods of making and using same |
| EP2085092A1 (en) * | 2008-01-29 | 2009-08-05 | Bayer Schering Pharma Aktiengesellschaft | Attenuated oncolytic paramyxoviruses encoding avian cytokines |
| JP2013500717A (ja) | 2009-07-28 | 2013-01-10 | コーニング インコーポレイテッド | 細胞を培養するための合成マイクロキャリア |
| WO2011032180A1 (en) * | 2009-09-14 | 2011-03-17 | Jennerex, Inc. | Oncolytic vaccinia virus combination cancer therapy |
-
2012
- 2012-08-03 WO PCT/US2012/049550 patent/WO2013022764A1/en not_active Ceased
- 2012-08-03 CA CA2841831A patent/CA2841831C/en active Active
- 2012-08-03 US US14/236,982 patent/US9719105B2/en active Active
- 2012-08-03 ES ES12746243T patent/ES2813413T3/es active Active
- 2012-08-03 CN CN201280038029.8A patent/CN103732236B/zh active Active
- 2012-08-03 AU AU2012294606A patent/AU2012294606B2/en not_active Ceased
- 2012-08-03 DK DK12746243.0T patent/DK2739293T3/da active
- 2012-08-03 BR BR112014000787-0A patent/BR112014000787B1/pt active IP Right Grant
- 2012-08-03 KR KR1020147005901A patent/KR102022952B1/ko active Active
- 2012-08-03 EP EP12746243.0A patent/EP2739293B1/en active Active
- 2012-08-03 JP JP2014524110A patent/JP6243333B2/ja active Active
- 2012-08-03 PL PL12746243T patent/PL2739293T3/pl unknown
-
2017
- 2017-06-27 US US15/634,765 patent/US10202581B2/en active Active
-
2019
- 2019-02-07 US US16/270,585 patent/US10767166B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2813413T3 (es) | 2021-03-23 |
| EP2739293A1 (en) | 2014-06-11 |
| US9719105B2 (en) | 2017-08-01 |
| CN103732236B (zh) | 2017-09-15 |
| EP2739293B1 (en) | 2020-06-10 |
| JP6243333B2 (ja) | 2017-12-06 |
| BR112014000787A2 (pt) | 2017-07-11 |
| JP2014521353A (ja) | 2014-08-28 |
| US10767166B2 (en) | 2020-09-08 |
| KR20140058601A (ko) | 2014-05-14 |
| CA2841831A1 (en) | 2013-02-14 |
| AU2012294606B2 (en) | 2016-10-06 |
| DK2739293T3 (da) | 2020-08-24 |
| US20140162342A1 (en) | 2014-06-12 |
| CA2841831C (en) | 2019-12-31 |
| WO2013022764A1 (en) | 2013-02-14 |
| US10202581B2 (en) | 2019-02-12 |
| US20190169578A1 (en) | 2019-06-06 |
| KR102022952B1 (ko) | 2019-09-20 |
| AU2012294606A1 (en) | 2014-01-23 |
| BR112014000787B1 (pt) | 2021-04-13 |
| US20170298324A1 (en) | 2017-10-19 |
| CN103732236A (zh) | 2014-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2739293T3 (pl) | Sposoby i kompozycje wytwarzania wirusa krowianki | |
| ZA201305150B (en) | Processes for preparing isoquinolinones and solid forms of isoquinolinones | |
| IL229830B (en) | Novel compinds as modulatord of gpr-119 | |
| IL229419B (en) | Heat-stable vaccines and methods for their preparation | |
| PH12013501969A1 (en) | Compositions and methods for inhibiting expression of tmprss6 gene | |
| ZA201307914B (en) | Compositions and methods for inhibiting gene expression of hepatitis b virus | |
| EP2712362A4 (en) | MANUFACTURE OF LACTO-N-TETRAOSE | |
| EP2771030A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF PROTEINOPATHIES | |
| ZA201306316B (en) | Methods and compositions for preparing noribogaine from voacangine | |
| GB2503842B (en) | Composition and method of manufacture | |
| EP2670790A4 (en) | METHOD FOR FLAME-RESISTANT POLYETHYLENE PROCESSED AT HIGH TEMPERATURES | |
| PL2785701T3 (pl) | Krystaliczna postać kabazytakselu i sposób jej otrzymywania | |
| EP2747975A4 (en) | MANUFACTURED ARTICLE AND PROCESS FOR PREPARING THE SAME | |
| GB201120696D0 (en) | Production of mono-cystalline silicon | |
| SG2014010441A (en) | Preparation process of l-methionine | |
| GB201220155D0 (en) | Method of manufacture | |
| GB201109416D0 (en) | Methods of mass spectrometry | |
| IL237862A0 (en) | Methods to reduce the formation of scale | |
| EP2684869A4 (en) | PREPARATION OF 3-MERCAPOTOPROPIONATES | |
| EP2780475A4 (en) | PROCESS FOR ALL-PECIFIC AMPLIFICATION | |
| IL239623A0 (en) | Methods and preparations for administering oxybutynin | |
| IL226329A0 (en) | A method @ for preparation @ from a tax salon | |
| SG11201402899TA (en) | Methods and compositions for treating viral diseases | |
| GB201114798D0 (en) | Method of modifying surfaces | |
| GB201119607D0 (en) | Method of manufacture |